The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Griffin, J. D.
Right arrow Articles by Schlossman, S. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griffin, J. D.
Right arrow Articles by Schlossman, S. F.

The Journal of Immunology, Vol 130, Issue 6 2947-2951, Copyright © 1983 by American Association of Immunologists

ARTICLES

Characterization of an antigen expressed by human natural killer cells

JD Griffin, T Hercend, R Beveridge and SF Schlossman

A monoclonal antibody, anti-N901, was produced by fusing NS-1 myeloma cells with spleen cells of a mouse immunized with human CML cells. This antibody was reactive with a subpopulation of peripheral blood LGL, including the natural killer cells. Monocytes, granulocytes, B cells, T cells (T3+ cells), erythrocytes, and platelets were nonreactive. The N901-positive cells in the peripheral blood were heterogeneous with respect to expression of other cell surface antigens. The majority of N901+ cells co-expressed T11, Mo1, and HNK-1, whereas a smaller percentage expressed T8. Ia, T3, T4, Mo2, or B1 antigens were very uncommon on N901+ cells. The heterogeneity of the N901+ LGL was further investigated by examining the expression of N901 antigen on a series of cloned normal human NK cell lines. N901 antigen was expressed by each of the NK cell lines tested, and by a minority of cloned T cell lines without NK activity. Anti-N901 does not block NK activity and can be used to rapidly purify functional NK cells for further study.


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
C. Assaf, S. Gellrich, S. Whittaker, A. Robson, L. Cerroni, C. Massone, H. Kerl, C. Rose, A. Chott, S. Chimenti, et al.
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of Cancer
J. Clin. Pathol., September 1, 2007; 60(9): 981 - 989.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. Introna, G. Borleri, E. Conti, M. Franceschetti, A. M. Barbui, R. Broady, E. Dander, G. Gaipa, G. D'Amico, E. Biagi, et al.
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study
Haematologica, July 1, 2007; 92(7): 952 - 959.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
S. Li, J. Xu, V. P. Makarenkova, T. Tjandrawan, J. Vakkila, T. Reichert, W. Gooding, C. F. Lagenaur, C. L. Achim, W. H. Chambers, et al.
A novel epitope of N-CAM defines precursors of human adherent NK cells
J. Leukoc. Biol., December 1, 2004; 76(6): 1187 - 1199.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. W. Bekkenk, P. M. Jansen, C. J. L. M. Meijer, and R. Willemze
CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature
Ann. Onc., July 1, 2004; 15(7): 1097 - 1108.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Tassone, A. Gozzini, V. Goldmacher, M. A. Shammas, K. R. Whiteman, D. R. Carrasco, C. Li, C. K. Allam, S. Venuta, K. C. Anderson, et al.
In Vitro and in Vivo Activity of the Maytansinoid Immunoconjugate huN901-N2'-Deacetyl-N2'-(3-Mercapto-1-Oxopropyl)-Maytansine against CD56+ Multiple Myeloma Cells
Cancer Res., July 1, 2004; 64(13): 4629 - 4636.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Suzuki, Y. Kagami, K. Takeuchi, M. Kami, M. Okamoto, R. Ichinohasama, N. Mori, M. Kojima, T. Yoshino, H. Yamabe, et al.
Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype
Blood, November 1, 2000; 96(9): 2993 - 3000.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. E. Schmitz, M. A. Forman, M. A. Lifton, O. Concepcion Jr, K. A. Reimann, C. S. Crumpacker, J. F. Daley, R. S. Gelman, and N. L. Letvin
Expression of the CD8alpha beta -Heterodimer on CD8+ T Lymphocytes in Peripheral Blood Lymphocytes of Human Immunodeficiency Virus- and Human Immunodeficiency Virus+ Individuals
Blood, July 1, 1998; 92(1): 198 - 206.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
O. Halaas, R. Vik, and T. Espevik
Induction of Fas Ligand in Murine Bone Marrow NK Cells by Bacterial Polysaccharides
J. Immunol., May 1, 1998; 160(9): 4330 - 4336.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. Suzuki, K. Yamamoto, M. Seto, Y. Kagami, M. Ogura, Y. Yatabe, T. Suchi, Y. Kodera, Y. Morishima, T. Takahashi, et al.
CD7+ and CD56+ Myeloid/Natural Killer Cell Precursor Acute Leukemia: A Distinct Hematolymphoid Disease Entity
Blood, September 15, 1997; 90(6): 2417 - 2428.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. Drenou, T. Lamy, L. Amiot, O. Fardel, S. Caulet-Maugendre, M. Sasportes, J. Diebold, P.-Y. Le Prise, and R. Fauchet
CD3-CD56+ Non-Hodgkin's Lymphomas With an Aggressive Behavior Related to Multidrug Resistance
Blood, April 15, 1997; 89(8): 2966 - 2974.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1983 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1983 by The American Association of Immunologists, Inc. All rights reserved.